The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
Open accessAbstract
Purpose: The main purpose of this study was to determine the prevalence of pathogenic BRCA1 and BRCA2 mutations in a consecutively ascertained clinic-based cohort of patients with pancreatic ductal adenocarcinoma and describe the clinical and family history characteristics. Patients and Methods: Unselected, consecutive, incident patients with pancreatic ductal adenocarcinoma were recruited at a single cancer center over a 2-year period. Participants provided blood for DNA analysis and cancer family history, and cancer treatment records were reviewed. DNA from all patients was analyzed by Sanger sequencing and multiplex ligation-dependent probe amplification for germline variants in BRCA1 and BRCA2. Results: Three hundred six patients were eligible for analysis. Pathogenic germline BRCA mutations were identified in 14 patients (4.6%; 95% CI, 2.2% to 6.9%), including 11 patients with a BRCA2 mutation and three patients with a BRCA1 mutation. Having a cancer family history that met genetic testing criteria of the National Comprehensive Cancer Network or the Ontario Ministry of Health and Long-Term Care or self-reporting as Ashkenazi Jewish was significantly associated with BRCA mutation carrier status (P = .02, P < .001, and P = .05, respectively). However, the majority of the BRCA mutation–positive patients did not actually meet these genetic testing criteria. Conclusion: Pathogenic BRCA mutations were identified in 4.6% of a large cohort of clinic-based patients. Considering the implications for family members of BRCA carriers, and possibly tailored chemotherapeutic treatment of patients, our finding has implications for broader BRCA genetic testing for patients with pancreatic ductal adenocarcinoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies estimate that genomic risk contributes to up to 8% of PDAC cases,180–184”
From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [184]
In the citing paper
“However, these classic features have poor sensitivity in identifying individuals at high genomic risk for pancreatic cancer.182–185”
From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [184]
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Cancer risks in BRCA2 mutation carriers.
Olsson, H. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,404
Cancer Incidence in BRCA1 mutation carriers.
Thompson, D., & Easton, D. (2002) · Journal of the National Cancer Institute · doi:10.1093/jnci/94.18.1358 · Cited by 1,231
Pennington, K. P., Walsh, T., Harrell, M. I., Lee, M. K., Pennil, C. C., Rendi, M. H., Thornton, A., Norquist, B. M., Casadei, S., Nord, A. S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2287 · Cited by 1,075
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 872
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C.-H., Palmisano, E., Brune, K., Jaffee, E. M., et al. (2009) · Science · doi:10.1126/science.1171202 · Cited by 826
Canto, M. I., Harinck, F., Hruban, R. H., Offerhaus, G. J., Poley, J.-W., Kamel, I., Nio, Y., Schulick, R. S., Bassi, C., Kluijt, I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303108 · Cited by 784
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B. P., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 678
Self-citationGermline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.
Goggins, M., Schutte, M. E. M., Lü, J., Moskaluk, C. A., Weinstein, C. L., Petersen, G. M., Yeo, C. J., Jackson, C. E., Lynch, H. T., Hruban, R. H., et al. (1996) · PubMed · Cited by 642
Flagged first, then by citations
Research works printed but not linked: 5
- Lal G, 2000, Cancer Res, 60, 409
- Tersmette AC, 2001, Clin Cancer Res, 7, 738
- Murphy KM, 2002, Cancer Res, 62, 3789
- Goggins M, 1996, Cancer Res, 56, 5360
- Levy-Lahad E, 1997, Am J Hum Genet, 60, 1059
Cited by
Sorted by citations
Items 201–300 of 401
The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer
Umemoto, K., & Sunakawa, Y. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103465 · Cited by 12
Cassese, G., Han, H., Yoon, Y., Lee, J. S., Lee, B., Cubisino, A., Panaro, F., & TROISI, R. I. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i6.911 · Cited by 11
Tan, H., & Hosein, P. J. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-85 · Cited by 11
Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma
Sarfraz, H. R., Saha, A., Jhaveri, K. S., & Kim, D. W. (2023) · Current Oncology · doi:10.3390/curroncol30060404 · Cited by 11
Metastatic Pancreatic Cancer: Where Are We?
Hernández-Blanquisett, A., Quintero-Carreño, V., Martínez‐Ávila, M. C., Porto, M., Barbur, M. C. M., & Buendía, E. (2024) · Oncology Reviews · doi:10.3389/or.2023.11364 · Cited by 13
Klein, A. P. (2023) · Wiley eBooks · doi:10.1002/9781119876007.ch124 · Cited by 11
Gastrointestinal cancer: molecular pathogenesis and targeted therapy
Jin, Y., He, X., & Wu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00361-9 · Cited by 13
Skorupan, N., Peer, C. J., Zhang, X., Choo‐Wosoba, H., Ahmad, M. I., Lee, M.-J., Rastogi, S., Sato, N., Yu, Y., Pegna, G. J., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1386190 · Cited by 10
Biomarkers in pancreatic ductal adenocarcinoma
Gallego-Plazas, J., López, C., Pazo-Cid, R., López‐Ríos, F., & Carrato, A. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1691-5 · Cited by 10
Barzola, E., López, E. V., Quijano, Y., Caruso, R. R. C., Ferri, V., Durand, H., Fabra, I., Eduardo, D., Ielpo, B., Glagolieva, A., et al. (2019) · Annals of Hepato-Biliary-Pancreatic Surgery · doi:10.14701/ahbps.2019.23.2.200 · Cited by 10
Integrated genomic analysis to identify druggable targets for pancreatic cancer
Mugiyanto, E., Adikusuma, W., Irham, L. M., Huang, W., Chang, W., & Kuo, C.-N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.989077 · Cited by 12
Two rare cancers of the exocrine pancreas: to treat or not to treat like ductal adenocarcinoma?
Skorupan, N., Ghabra, S., Maldonado, J. A., Zhang, Y., & Alewine, C. (2023) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.106 · Cited by 10
Tamaki, A., Kato, T., Sakurai, Y., Sato, K., Adachi, K., Tadehara, M., Kogami, T., Matsushita, M., Hoshino, A., Sanoyama, I., et al. (2023) · Cancer Science · doi:10.1111/cas.16044 · Cited by 9
Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma
Fong, C., Burke, E., Cunningham, D., & Starling, N. (2019) · Gastroenterology Research and Practice · doi:10.1155/2019/7135437 · Cited by 10
Wang, H., Mao, C., Li, N., Sun, L., Zheng, Y., & Xu, N. (2019) · Medicine · doi:10.1097/md.0000000000017443 · Cited by 10
Kimura, R., Ohtsuka, T., Kubo, M., Kajihara, A., Fujii, A., Watanabe, Y., Mori, Y., Ikenaga, N., Nakata, K., Shindo, K., et al. (2020) · Surgery Today · doi:10.1007/s00595-020-02123-2 · Cited by 10
DNA damage response and repair in pancreatic cancer development and therapy
Farnood, P. R., Pazhooh, R. D., Asemi, Z., & Yousefi, B. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103116 · Cited by 11
The Dual Role of Necroptosis in Pancreatic Ductal Adenocarcinoma
Giansante, V., Stati, G., Sancilio, S., Guerra, E., Alberti, S., & Pietro, R. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612633 · Cited by 10
Emerging Treatment Strategies in Pancreatic Cancer
Trunk, A. D., Miotke, L. K., Nevala-Plagemann, C., Verdaguer, H., Macarulla, T. M., & Garrido‐Laguna, I. (2021) · Pancreas · doi:10.1097/mpa.0000000000001845 · Cited by 11
Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer
Marin, A. M., Sanchuki, H. B. S., Namur, G. N., Uno, M., Zanette, D. L., & Aoki, M. N. (2023) · Biomedicines · doi:10.3390/biomedicines11041069 · Cited by 9
Koukaki, T., Balgkouranidou, I., Biziota, E., Karayiannakis, A. J., Bolanaki, H., Karamitrousis, E., Zarogoulidis, P., Deftereos, S. P., Charalampidis, C., Ioannidis, A., et al. (2024) · Journal of Cancer · doi:10.7150/jca.93184 · Cited by 9
Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma
Blair, A. B., Radomski, S. N., Chou, J. F., Liu, M., Howell, T. C., Park, W., O'Reilly, E. M., Zheng, L., Balachandran, V. P., Wei, A. C.-C., et al. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-16331-4 · Cited by 9
Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma
Zhen, D. B., Coveler, A. L., Zanon, S. M., Reni, M., & Chiorean, E. G. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.05.004 · Cited by 9
Pimenta, J. R., Ueda, S. K. N., & Peixoto, R. D. (2020) · Case Reports in Oncology · doi:10.1159/000508533 · Cited by 9
Application of natural killer cells in pancreatic cancer (Review)
Peng, X., Chen, L., Yuan, J., Wang, Y., Hao, Z., & Zhan, X. (2021) · Oncology Letters · doi:10.3892/ol.2021.12908 · Cited by 9
Pancreatic cancer: genetics, disease progression, therapeutic resistance and treatment strategies
Singh, K., Shishodia, G., & Koul, H. K. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.96 · Cited by 9
The role of PARP inhibitors in gastrointestinal cancers
Hanna, D., Chopra, N., Hochhauser, D., & Khan, K. H. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103621 · Cited by 9
Genomic landscape of pancreatic cancer in the Japanese version of the Cancer Genome Atlas
Imamura, T., Ashida, R., Ohshima, K., Uesaka, K., Sugiura, T., Okamura, Y., Ohgi, K., Ohnami, S., Nagashima, T., & Yamaguchi, K. (2022) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12636 · Cited by 7
Kubo, T., Muramatsu, J., Arihara, Y., Murota, A., Ishikawa, K., Yoshida, M., Nagashima, H., Tamura, F., Ikeda, Y., Usami, M., et al. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad131 · Cited by 8
Clinical features of germline BRCA1/2 or ATM pathogenic variant positive pancreatic cancer in Japan
Kitamura, H., Morizane, C., Tanabe, N., Ikeda, G., Maruki, Y., Ohba, A., Nagashio, Y., Kondo, S., Hijioka, S., Ueno, H., et al. (2023) · Pancreatology · doi:10.1016/j.pan.2023.10.017 · Cited by 8
Cao, C., Sharib, J. M., Blanco, A. M., Goldberg, D., Bracci, P. M., Mukhtar, R. A., Esserman, L. J., & Kirkwood, K. S. (2019) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2019.09.019 · Cited by 8
The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Moffat, G. T., & O'Reilly, E. M. (2020) · PubMed · Cited by 8
Zhan, M., Zheng, H., Yu, Y., He, Z., Xu, T., & Li, Q. (2020) · Cancer Management and Research · doi:10.2147/cmar.s283169 · Cited by 8
Sharma, V., & Sharma, A. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_107_21 · Cited by 8
Pijnappel, E. N., Suurmeijer, J. A., Koerkamp, B. G., Kos, M., Siveke, J. T., Salvia, R., Ghaneh, P., van Eijck, C. H. J., van Etten‐Jamaludin, F. S., Abrams, R. A., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0168 · Cited by 8
McGarry, J., Creavin, B., Kelly, M. E., & Gallagher, T. K. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.26994 · Cited by 8
Voutsadakis, I. A., & Digklia, A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45030135 · Cited by 8
Verdaguer, H., Arroyo, A., & Macarulla, T. M. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0609-7 · Cited by 8
Talking Genes in Breast and Pancreatic Malignancies
Barbara, M., Tsen, A., Tenner, L. L., & Rosenkranz, L. A. (2019) · Materia Socio Medica · doi:10.5455/msm.2019.31.146-149 · Cited by 8
Dwarte, T. M., McKay, S., Johns, A. L., Tucker, K., Spigelman, A. D., Williams, D. B., & Stoita, A. (2019) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-019-0129-1 · Cited by 8
Achieving ‘Marginal Gains’ to Optimise Outcomes in Resectable Pancreatic Cancer
Powell-Brett, S. F., Pandé, R., & Roberts, K. J. (2021) · Cancers · doi:10.3390/cancers13071669 · Cited by 9
Chen, Z., Wang, K., Zhao, L., & Gong, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1190100 · Cited by 7
S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1
Seufferlein, T. T. W., Mayerle, J. V., Boeck, S. H., Brunner, T. B., Ettrich, T. J., Grenacher, L., Gress, T. M., Hackert, T., Heinemann, V., Kestler, A. M. R., et al. (2024) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2338-3533 · Cited by 7
Men seeking counselling in a Breast Cancer Risk Evaluation Clinic
Freitas, A. C., Opinião, A., Fragoso, S., Nunes, H., Santos, M., Clara, A. I., Bento, S., Luis, A. S., Silva, J. A. M. D. C., Moura, C., et al. (2018) · ecancermedicalscience · doi:10.3332/ecancer.2018.804 · Cited by 8
Nouvelle AMM : olaparib — cancer du pancréas avec mutation germinale de BRCA
Hilmi, M., & Neuzillet, C. (2020) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.06.009 · Cited by 7
Anandakrishnan, R., Carpenetti, T. L., Samuel, P., Wasko, B., Johnson, C., Smith, C., Kim, J. J., Michalak, P., Kang, L., Kinney, N., et al. (2020) · BMC Medical Education · doi:10.1186/s12909-020-02366-0 · Cited by 7
Hsieh, A., Pitarresi, J. R., Lerner, J., Donahue, G., Hsiehchen, D., Rustgi, A. K., & Zaret, K. S. (2020) · Science Advances · doi:10.1126/sciadv.abc4517 · Cited by 7
Saldia, A., Olson, S. H., Nunes, P., Liang, X., Samson, M. L., Salo‐Mullen, E. E., Marcell, V. J., Stadler, Z. K., Allen, P. J., Offit, K., et al. (2019) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-18-0272 · Cited by 7
An unusual genomic variant of pancreatic ductal adenocarcinoma with an indolent clinical coursePreprint
Kohutek, Z. A., Rosati, L. M., Hong, J., Poling, J., Attiyeh, M. A., Makohon-Moore, A. P., Herman, J. M., & Iacobuzio–Donahue, C. A. (2017) · Molecular Case Studies · doi:10.1101/mcs.a001701 · Cited by 7
Bahng, I. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1713123 · Cited by 6
Genomic Characterization of Preclinical Prostate Cancer Cell Line Models
Beatson, E. L., Risdon, E. N., Napoli, G. C., Price, D. K., Chau, C. H., & Figg, W. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116111 · Cited by 6
Valdez, B. C., Tsimberidou, A. M., Yuan, B., Nieto, Y. L., Baysal, M. A., Chakraborty, A., Andersen, C. R., & Andersson, B. S. (2024) · Oncotarget · doi:10.18632/oncotarget.28588 · Cited by 6
Preoperative Prognostic Factors in Resectable Pancreatic Cancer: State of the Art and Prospects
Boubaddi, M., Rossi, J., Marichez, A., Marty, M., Amintas, S., Laurent, C., & Dabernat, S. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17062-w · Cited by 6
Peters, N. V., & Kunstman, J. W. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.67 · Cited by 6
Blackford, A. L., Childs, E. J., Porter, N. R., Petersen, G. M., Rabe, K. G., Gallinger, S., Borgida, A., Syngal, S., Coté, M. L., Schwartz, A. G., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01580-x · Cited by 6
Self-citationDescriptive, analytical and molecular epidemiology of pancreatic cancer
Shangina, O., Maximovich, D. M., & Zaridze, D. G. (2022) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2022-21-3-90-103 · Cited by 6
Khaled, N. B., Hammer, K., Ye, L., Alnatsha, A., Widholz, S. A., Piseddu, I., Sirtl, S., Schneider, J. A., Munker, S., Mahajan, U. M., et al. (2022) · Cancers · doi:10.3390/cancers14215240 · Cited by 7
Rapposelli, I. G., Zampiga, V., Cangini, I., Arcangeli, V., Ravegnani, M., Valgiusti, M., Pini, S., Tamberi, S., Bartolini, G., Passardi, A., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08368-5 · Cited by 7
Roberts, N. J., & Klein, A. P. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_78 · Cited by 6
Weitzel, J. N. (2015) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2015.06.011 · Cited by 6
Grant, R. C., Holter, S., Borgida, A., Dhani, N. C., Hedley, D. W., Knox, J. J., Akbari, M. R., Zogopoulos, G., & Gallinger, S. (2018) · Journal of Genetic Counseling · doi:10.1007/s10897-018-0212-1 · Cited by 6
Self-citationShould We Lower Our Threshold for Germline Genetic Assessment in Pancreatic Adenocarcinoma?
Latham, A. J., & Stadler, Z. K. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00227 · Cited by 7
Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy
Geerinckx, B., Teuwen, L.-A. M. N., Foo, T., Vandamme, T., Smith, A., Peeters, M., & Price, T. J. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2270161 · Cited by 5
Buchberg, J., de Stricker, K., Pfeiffer, P., Mortensen, M. B., & Detlefsen, S. (2024) · Endoscopic Ultrasound · doi:10.1097/eus.0000000000000072 · Cited by 6
Clinical Application of PARP1 Inhibitors and Challenges in Cancer Therapy
Luo, Y., Nie, M., Chen, Y., Huang, X., Cui, X., Lin, W., Xu, L., Li, E., & Cheng, Y. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096327635241021115944 · Cited by 6
Fulton, A., Lamarca, Á., Nuttall, C., McCallum, L., Pihlak, R., O'Reilly, D. A., Lalloo, F. I., McNamara, M. G., Hubner, R. A., Clancy, T., et al. (2019) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v11.i2.102 · Cited by 5
Terashima, T., Morizane, C., Ushiama, M., Shiba, S., Takahashi, H., Ikeda, M., Mizuno, N., Tsuji, K., Yasui, K., Azemoto, N., et al. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac110 · Cited by 5
Tavano, F., Gioffreda, D., Fontana, A., Palmieri, O., Gentile, A., Latiano, T. P., Latiano, A., Latiano, T. P., Scaramuzzi, M., Maiello, E., et al. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00600-1 · Cited by 5
Wei, M., Liu, R., Xu, Y., Chen, X., Liu, C., Bai, X., Zhang, X., Gao, S., Li, J., Sheng, Z., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03581-y · Cited by 5
Matsubayashi, H., Kiyozumi, Y., & Ono, H. (2025) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.12112 · Cited by 5
Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients
Yin, X., Shen, H., Wang, H., Wang, Q., Zhang, S., Zhang, C., Jia, Q., Guo, S., Xu, X., Zhang, W., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57520-3 · Cited by 5
PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer
Desai, D., Khandwala, P., Parsi, M., & Potdar, R. R. (2021) · Medical Oncology · doi:10.1007/s12032-021-01507-9 · Cited by 5
Wu, S., Ren, J., Qian, W., Gong, M., Li, J., Qin, T., Zhang, S., Zhang, W., Sun, H., Wu, Z. Q., et al. (2023) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000160 · Cited by 4
Qureshi, M. J., Narde, G. K., Ahuja, A., Meenakshi, D. U., & Al-Balushi, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157350 · Cited by 4
Beutel, A. K., Halbrook, C. J., Ekizce, M., Lindenmayer, J., Roger, É., Calderon, S. E., Seufferlein, T. T. W., Kleger, A., Gout, J., & Perkhofer, L. (2025) · United European Gastroenterology Journal · doi:10.1002/ueg2.12773 · Cited by 4
Understanding familial risk of pancreatic ductal adenocarcinoma
Paranal, R. M., Wood, L. D., Klein, A. P., & Roberts, N. J. (2024) · Familial Cancer · doi:10.1007/s10689-024-00383-2 · Cited by 4
Milella, M., Orsi, G., Marco, M. D., Salvatore, L., Procaccio, L., Noventa, S., Bozzarelli, S., Garajová, I., Vasile, E., Giordano, G., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.70364 · Cited by 4
How to Screen for Hereditary Cancers in General Pathology Practice
Sheffield, B. S., Hirsch‐Reinshagen, V., & Schrader, K. A. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0457-ra · Cited by 4
A novel somatic BRCA2 point mutation in a metastatic pancreatic cancer patient: a case report
Wang, D., Guan, R., Qing, T., Liu, S., Yu, M., & Li, X. (2021) · BMC Medical Genomics · doi:10.1186/s12920-020-00850-6 · Cited by 4
Hue, J. J., Bingmer, K. E., Sugumar, K., Markt, S. C., Rothermel, L. D., Hardacre, J. M., Ammori, J. B., Winter, J. M., & Ocuin, L. M. (2021) · Journal of Pancreatic Cancer · doi:10.1089/pancan.2021.0003 · Cited by 4
Rapposelli, I. G., Gardini, A. C., Vivaldi, C., Bartolini, G., Bernardini, L., Passardi, A., Frassineti, G. L., Massa, V., & Cucchetti, A. (2021) · Biomolecules · doi:10.3390/biom11060780 · Cited by 4
Pancreatic Cancer: Beyond Brca Mutations
Ricci, V., Fabozzi, T., Bareschino, M. A., Barletta, E., Germanò, D., Paciolla, I., Tinessa, V., & Grimaldi, A. M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12122076 · Cited by 4
Endoscopic ultrasound-guided tissue acquisition for comprehensive genomic profiling
Okuno, N., & Hara, K. (2024) · Journal of Medical Ultrasonics · doi:10.1007/s10396-023-01403-x · Cited by 4
Kawamoto, Y., Yamai, T., Ikezawa, K., Seiki, Y., Watsuji, K., Hirao, T., Urabe, M., Kai, Y., Takada, R., Mukai, K., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12722-8 · Cited by 4
Boeck, S. H., Mehraein, Y., Ormanns, S., Krüger, S., Westphalen, C. B., Haas, M., Jung, A., Kirchner, T., & Heinemann, V. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw564 · Cited by 4
Incidence of Pathogenic Variants in Those With a Family History of Pancreatic Cancer
Macklin, S., Kasi, P. M., Jackson, J. L., & Hines, S. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00330 · Cited by 4
Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer
Kato, S. (2021) · Diagnostics · doi:10.3390/diagnostics11020252 · Cited by 4
Prete, A. A., Procaccio, L., Bergamo, F., Rasola, C., Nappo, F., Zagonel, V., & Lonardi, S. (2022) · Current Oncology · doi:10.3390/curroncol29020049 · Cited by 4
Roberts, N. J., & Klein, A. P. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_78-1 · Cited by 4
Molecular Biomarkers for the Diagnosis and Prognostication of Pancreatic Ductal Adenocarcinoma
Sun, J. X., Awad, M. A., Hwang, J., & Villano, A. M. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15060236 · Cited by 6
Diagnosis and Management of Hereditary Pancreatic Cancer
Humphris, J. L., & Biankin, A. V. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-29998-3_5 · Cited by 3
Hereditary Breast Cancer: BRCA and Other Susceptibility Genes
Azzollini, J., Fontana, L., & Manoukian, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-41207-4_3 · Cited by 3
Zhang, Z., Sun, W., Zeng, Z., & Lu, Y. (2022) · Acta Biochimica Polonica · doi:10.18388/abp.2020_5758 · Cited by 3
Deficits of Molecular Prognosis/Diagnosis Studies in Underserved Populations
Medford, A. J., & Moy, B. (2024) · JCO Oncology Practice · doi:10.1200/op.24.00131 · Cited by 3
Mandatory Reporting Measurements in Trials for Potentially Resectable Pancreatic Cancer
Pijnappel, E. N., Suurmeijer, J. A., Koerkamp, B. G., Siveke, J. T., Salvia, R., Ghaneh, P., Besselink, M. G., Wilmink, J. W., & van Laarhoven, H. W. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_8 · Cited by 3
Familial pancreatic cancer: who should be considered for genetic testing?
Kartal, K., Guan, Z., Tang, R., Griffin, M., Wang, Y., Braun, D., Klein, A. P., & Hughes, K. S. (2021) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02572-9 · Cited by 3
Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer
Sunkara, T., Bandaru, S. S., Boyilla, R., Kunadharaju, R., Kukkadapu, P., & Chennamadhavuni, A. (2022) · Cureus · doi:10.7759/cureus.22575 · Cited by 4
Damanakis, A. I., Gebauer, F., & Bruns, C. J. (2020) · Der Chirurg · doi:10.1007/s00104-020-01172-0 · Cited by 3
Marco, M. D., Carloni, R., Lorenzo, S. D., Mosconi, C., Palloni, A., Grassi, E., Filippini, D. M., Ricci, A. D., Rizzo, A., Federico, A. D., et al. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i12.1456 · Cited by 3
Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King
Attiyeh, M. A., Amini, A., Chung, V. M., & Melstrom, L. G. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26415 · Cited by 3
Metadata
- Authors
- Holter, S., Borgida, A., Dodd, A., Grant, R., Semotiuk, K., Hedley, D., Dhani, N., Narod, S., Akbari, M., Moore, M., & Gallinger, S.
- Affiliations
- Mount Sinai Hospital (CA)
- Spring Holter, Ayelet Borgida, Robert Grant, Kara Semotiuk, and Steven Gallinger, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital; Anna Dodd, David Hedley, Neesha Dhani, Malcolm Moore, and Steven Gallinger, McCain Pancreatic Cancer Centre, University Health Network; and Steven Narod and Mohammad Akbari, Women's College Research Institute, Toronto, Ontario, Canada.
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2015-10-01
- Volume
- 33
- Issue
- 28
- Pages
- 3124-3129
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2161479848
- Cited by
- 398
- References
- 39
- Citations by year
- 2026: 18 · 2025: 19 · 2024: 23 · 2023: 40 · 2022: 40 · 2021: 71 · 2020: 50 · 2019: 27 · 2018: 42 · 2017: 30 · 2016: 26 · 2015: 12
- FWCI
- 25.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Cancer Society Research Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- germline BRCA1 mutation, germline BRCA2 mutation, pancreatic ductal adenocarcinoma, family history of cancer, Ashkenazi Jewish ancestry, hereditary cancer predisposition
- MeSH terms
- Adult, Aged, Aged, 80 and over, DNA Mutational Analysis, Female, Gene Frequency, Humans, Jews, Male, Middle Aged, Ontario, Pancreatic Neoplasms, Pedigree, Phenotype, Prognosis, Prospective Studies, Risk Factors, Incidence, Germ-Line Mutation, BRCA1 Protein, Genetic Predisposition to Disease, Carcinoma, Pancreatic Ductal, BRCA2 Protein, Heredity, Multiplex Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review